Journal of the American Academy of Dermatology
Volume 63, Issue 2 , Pages 252-258 , August 2010

Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study

  • Hee Chul Eun, MD

      Affiliations

    • Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea
    • Corresponding Author InformationReprint requests: Hee Chul Eun, MD, Department of Dermatology, Seoul National University College of Medicine, Seoul National University Hospital, 101, Daehang-ro, Jongno-gu, Seoul, 110-744 Korea.
    • ,
  • Oh Sang Kwon, MD

      Affiliations

    • Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea
    • ,
  • Je Ho Yeon, MD

      Affiliations

    • Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea
    • ,
  • Hyo Seung Shin, MD

      Affiliations

    • Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea
    • ,
  • Byung Yoon Kim, MD

      Affiliations

    • Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea
    • ,
  • Byung In Ro, MD

      Affiliations

    • Department of Dermatology, Kwandong University College of Medicine, Koyang, Kyunggi, Korea
    • ,
  • Han Kyong Cho, MD

      Affiliations

    • Department of Dermatology, Kwandong University College of Medicine, Koyang, Kyunggi, Korea
    • ,
  • Woo Young Sim, MD

      Affiliations

    • Department of Dermatology, College of Medicine, Kyong Hee University, Seoul, Korea
    • ,
  • Bark Lynn Lew, MD

      Affiliations

    • Department of Dermatology, College of Medicine, Kyong Hee University, Seoul, Korea
    • ,
  • Won-Soo Lee, MD

      Affiliations

    • Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Korea
    • Institute of Hair and Cosmetic Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea
    • ,
  • Hwa Young Park, MD

      Affiliations

    • Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Korea
    • ,
  • Seung Phil Hong, MD

      Affiliations

    • Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Korea
    • ,
  • Jae Hong Ji, MD

      Affiliations

    • Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Korea

,Accepted 8 September 2009.

References 

  1. Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68:1359–1365
  2. Hamilton JB. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci. 1951;53:708–728
  3. Cash TF. The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol. 1992;26:926–931
  4. Olsen EA. Androgenetic alopecia. In:  Olsen EA editors. Disorders of hair growth: diagnosis and treatment. New York: McGraw-Hill; 1994;p. 257–283
  5. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974;186:1213–1215
  6. Jenkins EP, Andersson S, Imperato-McGinley J, Wilson JD, Russell DW. Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase. J Clin Invest. 1992;89:293–300
  7. Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem. 1994;63:25–61
  8. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest. 1993;92:903–910
  9. Bramson HN, Hermann D, Batchelor KW, Lee FW, James MK, Frye SV. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther. 1997;282:1496–1502
  10. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C, et al. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004;46:488–494
  11. Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology. 2004;63:709–715
  12. Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55:1014–1023
  13. Price VH. Treatment of hair loss. N Engl J Med. 1999;341:964–973
  14. Olsen EA, Messenger AG, Shapiro J, Bergfeld WF, Hordinsky MK, Roberts JL, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005;52:301–311
  15. Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39:578–589
  16. Stough D. Dutasteride improves male pattern hair loss in a randomized study in identical twins. J Cosmet Dermatol. 2007;6:9–13
  17. Olszewska M, Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol. 2005;4:637–640
  18. Canfield D. Photographic documentation of hair growth in androgenetic alopecia. Dermatol Clin. 1996;41:713–721
  19. Randall VA, Ebling FJ. Seasonal changes in human hair growth. Br J Dermatol. 1991;124:146–151
  20. Courtois M, Loussouarn G, Hourseau S, Grollier JF. Periodicity in the growth and shedding of hair. Br J Dermatol. 1996;134:47–54
  21. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89:2179–2184
  22. Dallob AL, Sadick NS, Unger W, Lipert S, Geissler LA, Gregoire SL, et al. The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab. 1994;79:703–706

 Supported by GlaxoSmithKline.

 Conflicts of interest: None declared.

PII: S0190-9622(09)01213-4

doi: 10.1016/j.jaad.2009.09.018

Journal of the American Academy of Dermatology
Volume 63, Issue 2 , Pages 252-258 , August 2010

Article Tools

* Image Usage & Resolution